Who can use Datroway(DatopotamabDeruxtecan-dlnk)?

DATROWAY is approved for treating a specific type of advanced breast cancer in adults.

Indications

DATROWAY is indicated for adult patients with unresectable or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer, as confirmed by IHC 0, IHC 1+, or IHC 2+/ISH- testing. Eligible patients must have previously received endocrine-based therapy and chemotherapy for their advanced disease. This approval is based on clinical trial data demonstrating efficacy in this population, providing a new treatment option after prior systemic therapies have been used.

Related Columns

DatopotamabDeruxtecan-dlnk(Datroway)

Treatment of unresectable or metastatic HR-positive, HER2-negative breast...

WeChat Scan
Free Inquiry

What Are the Indications for Datroway (Datopotamab Deruxtecan)?

Datroway (datopotamab deruxtecan) is an innovative Trop-2-directed antibody-drug conjugate (ADC) that provides a new treatment option for patients with specific types of metastatic breast cancer. Comb...

Indications for Datopotamab Deruxtecan (Datroway)

Datopotamab Deruxtecan (Datroway) is a novel Trop-2-directed antibody-drug conjugate (ADC) linked to a topoisomerase inhibitor. It has demonstrated favorable efficacy in the treatment of specific type...